Asher Bio raises USD 55 Million in Series A financing Asher Biotherapeutics, a biotechnology company developing exactly targeted immunotherapies for cancer and other diseases, raised USD 55 Million in Series A financing. Third Rock Ventures led the round with participation from Boxer Capital of Tavistock Grou...
Find MoreValo Health receives USD 110 Million Series B from Koch Valo Health launched in September with USD 100 million and a couple of acquisitions under its belt to transform drug development and cut years off R&D timelines. Now, it is filling with USD 110 million from Koch Disruptive Technologies that will bolster...
Find MoreUnshackling the TP53 in leukaemia with a novel combination approach. Drugs that target the cancer-promoting proteins MDM2 and BET have been attempted in acute myeloid leukaemia (AML) and have not been all that effective on their own. However, they might be useful if they were combined. Researchers...
Find MoreRoche receives FDA authorization for the quantitative COVID-19 antibody test Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. The company anticipates the tes...
Find MoreBASE10 Collaborates with DNA Link for COVID-19 Antibody Test Research US-based BASE10 Genetics and Korean firm DNA Link announced a collaboration on a research project to appraise the usability of the DNA Link's antibody test, AccuFind COVID-19 IgG, in a healthcare setting. Currently, most antibody tests avai...
Find MoreFDA authorizes first diagnostic test for COVID-19 antibodies that obstruct the virus from entering cells The FDA has authorized the first COVID-19 diagnostic test, which identifies whether a person has the specific antibodies known to hinder the coronavirus from entering and infecting human cells. These neutr...
Find MoreFDA nods Boston Scientific's paclitaxel-coated Ranger balloon for peripheral artery disease Boston Scientific has received the FDA approval for its Ranger paclitaxel-coated balloon, designed to restrict a patient's systemic exposure to the chemotherapy used to reduce the closure of reopened arteries. The slim...
Find MoreBayer Set to Fork Over USD 4 Billion for AskBio’s Gene Therapies Germany-based Bayer is set to acquire North Carolina-based Asklepios BioPharmaceutical (AskBio) with motives to get its hands on its gene therapies. Bayer will pay USD 2 billion in upfront payment in exchange for AskBio's AAV-based gene th...
Find MoreMyoKardia Buyout: BMS expands its cardiovascular portfolio for USD 13.1 Billion Bristol Myers Squibb has bounty years in a go with its shares skyrocketing as it decides to go on an acquisition spree. BMS has announced to acquire MyoKardia, a pharmaceutical company leveraging precision medicine to ...
Find MoreMorphoSys, Incyte gets an early FDA nod for Monjuvi, an alternative to CAR-T for B-cell malignancies MorphoSys and Incyte announced the US FDA approval under accelerated approval for their treatment Monjuvi in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymp...
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.